• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期 Masaoka-Koga 分期 III 胸腺瘤根治性放疗与肿瘤减灭术对治疗结局和预后的影响。

Impact of Definitive Radiotherapy and Surgical Debulking on Treatment Outcome and Prognosis for Locally Advanced Masaoka-Koga stage III Thymoma.

机构信息

Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

Department of Cancer Epidemiology, Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

出版信息

Sci Rep. 2020 Feb 3;10(1):1735. doi: 10.1038/s41598-020-58692-2.

DOI:10.1038/s41598-020-58692-2
PMID:32015469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6997365/
Abstract

The role of definitive radiotherapy (dRT) and debulking surgery (DS) for patients with locally advanced, unresectable, Masaoka-Koga stage III thymomas was not well studied. Unresectable tumor refers to tumor that could not be completely resected because of invasion of surrounding organs. Consecutive patients with unresectable stage III thymomas between 2000 and 2017 were reviewed. According to the treatment intent and radiation dose, patients were categorized into a dRT group and a non-dRT group. The former group included patients who received radiotherapy at doses ≥ 54 Gy after DS or biopsy. The latter group included patients who did not receive radiotherapy and those who received a radiation dose < 54 Gy. A total of 82 patients were included. Compared with non-dRT, dRT significantly improved 5-year overall survival (OS, P = 0.003), progression-free survival (PFS, P = 0.008), and freedom from locoregional failure (FFLF, P < 0.001). Compared with biopsy alone, DS did not improve OS, PFS, FFLF. On multivariate analysis, dRT was an independent prognostic factor for OS (hazard ratio [HR]: 2.37, P = 0.024), PFS (HR: 2.40, P = 0.004), and FFLF (HR: 3.83, P = 0.001). In conclusion, dRT was an effective and beneficial treatment for patients with unresectable Masaoka-Koga stage III thymoma.

摘要

根治性放疗(dRT)和减瘤手术(DS)在局部晚期、不可切除、Masaoka-Koga 分期 III 期胸腺瘤患者中的作用尚未得到充分研究。不可切除的肿瘤是指由于周围器官的侵犯而无法完全切除的肿瘤。回顾了 2000 年至 2017 年间连续的不可切除 III 期胸腺瘤患者。根据治疗目的和放射剂量,患者分为 dRT 组和非 dRT 组。前者组包括在 DS 或活检后接受剂量≥54Gy 放疗的患者。后者组包括未接受放疗和接受剂量<54Gy 放疗的患者。共纳入 82 例患者。与非 dRT 相比,dRT 显著提高了 5 年总生存率(OS,P=0.003)、无进展生存率(PFS,P=0.008)和无局部区域失败生存率(FFLF,P<0.001)。与单独活检相比,DS 并未改善 OS、PFS、FFLF。多因素分析显示,dRT 是 OS(风险比 [HR]:2.37,P=0.024)、PFS(HR:2.40,P=0.004)和 FFLF(HR:3.83,P=0.001)的独立预后因素。总之,dRT 是治疗不可切除的 Masaoka-Koga 分期 III 期胸腺瘤患者的有效且有益的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940c/6997365/12d4f9d3c14a/41598_2020_58692_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940c/6997365/12d4f9d3c14a/41598_2020_58692_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940c/6997365/12d4f9d3c14a/41598_2020_58692_Fig1_HTML.jpg

相似文献

1
Impact of Definitive Radiotherapy and Surgical Debulking on Treatment Outcome and Prognosis for Locally Advanced Masaoka-Koga stage III Thymoma.局部晚期 Masaoka-Koga 分期 III 胸腺瘤根治性放疗与肿瘤减灭术对治疗结局和预后的影响。
Sci Rep. 2020 Feb 3;10(1):1735. doi: 10.1038/s41598-020-58692-2.
2
Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic Carcinoma.减瘤手术加放疗:不可切除的Ⅲ期胸腺癌的治疗选择
Thorac Cardiovasc Surg. 2020 Aug;68(5):440-445. doi: 10.1055/s-0039-1688723. Epub 2019 May 28.
3
Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database.局部晚期胸腺瘤的多模态治疗:一项来自欧洲胸外科医师协会数据库的倾向评分匹配队列研究。
J Thorac Cardiovasc Surg. 2016 Jan;151(1):47-57.e1. doi: 10.1016/j.jtcvs.2015.08.034. Epub 2015 Aug 15.
4
Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma: A Retrospective Multicenter Study.晚期侵袭性胸腺瘤或胸腺癌患者的治疗方式及预后:一项回顾性多中心研究
Am J Clin Oncol. 2016 Apr;39(2):120-5. doi: 10.1097/COC.0000000000000024.
5
Outcome of multimodality treatment for 188 cases of type B3 thymoma.188 例 B3 型胸腺瘤多模态治疗的结果。
J Thorac Oncol. 2013 Oct;8(10):1329-34. doi: 10.1097/JTO.0b013e31829ceb50.
6
Thymomas and thymic carcinomas: prognostic factors and multimodal management.胸腺瘤和胸腺癌:预后因素与多模式管理
Thorac Cardiovasc Surg. 2014 Mar;62(2):153-60. doi: 10.1055/s-0032-1322611. Epub 2012 Dec 6.
7
Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer.侵袭性胸腺瘤的放疗与化疗:90例多中心回顾性研究。法国国立癌症中心联合会(FNCLCC)试验组
Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):651-9. doi: 10.1016/0360-3016(95)00079-e.
8
Improved survival with postoperative radiotherapy in thymic carcinoma: A propensity-matched analysis of Surveillance, Epidemiology, and End Results (SEER) database.胸腺癌术后放疗可提高生存率:基于监测、流行病学和最终结果(SEER)数据库的倾向匹配分析
Lung Cancer. 2017 Jun;108:161-167. doi: 10.1016/j.lungcan.2017.03.020. Epub 2017 Mar 31.
9
The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma.胸腺瘤和胸腺癌术后放疗的影响。
J Thorac Oncol. 2017 Apr;12(4):734-744. doi: 10.1016/j.jtho.2017.01.002. Epub 2017 Jan 25.
10
Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study.III期胸腺瘤:手术及术后放疗后的失败模式及其对未来研究的启示
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):927-33. doi: 10.1016/s0360-3016(99)00514-3.

引用本文的文献

1
Results of radiotherapy for thymoma: retrospective cohort and propensity score matching analysis.胸腺瘤放疗结果:回顾性队列研究与倾向评分匹配分析
J Bras Pneumol. 2025 Sep 8;51(3):e20240331. doi: 10.36416/1806-3756/e20240331. eCollection 2025.
2
Re-evaluation and operative indications after induction therapy for thymic epithelial tumors.胸腺上皮肿瘤诱导治疗后的重新评估及手术指征
Mediastinum. 2024 Jun 4;8:43. doi: 10.21037/med-23-70. eCollection 2024.
3
Hypofractionated Radiotherapy as a Standalone Treatment Modality for Locally Advanced Type B2 Thymoma in an Octogenarian Patient: 45 Gy in 15 Fractions.

本文引用的文献

1
Concurrent chemoradiotherapy for unresectable thymic carcinoma.不可切除胸腺癌的同步放化疗
Chang Gung Med J. 2004 Jul;27(7):515-22.
2
Managements of locally advanced unresectable thymic epithelial tumors.局部晚期不可切除胸腺上皮肿瘤的治疗
J Chin Med Assoc. 2004 Apr;67(4):172-8.
超分割放疗作为一名八旬老人局部晚期B2型胸腺瘤的单一治疗方式:15次分割给予45 Gy
Cureus. 2024 Jan 2;16(1):e51528. doi: 10.7759/cureus.51528. eCollection 2024 Jan.
4
Outcomes of extended surgical resections for locally advanced thymic malignancies: a narrative review.局部晚期胸腺恶性肿瘤扩大手术切除的疗效:一项叙述性综述
Gland Surg. 2022 Mar;11(3):611-621. doi: 10.21037/gs-21-642.
5
"Radiotherapy for thymic epithelial tumors: What is the optimal dose? A systematic review.".胸腺瘤的放射治疗:最佳剂量是多少?一项系统评价。
Clin Transl Radiat Oncol. 2022 Mar 19;34:67-74. doi: 10.1016/j.ctro.2022.03.005. eCollection 2022 May.
6
Development of a competing risk nomogram for the prediction of cause-specific mortality in patients with thymoma: a population-based analysis.胸腺瘤患者特定病因死亡率预测的竞争风险列线图的开发:一项基于人群的分析
J Thorac Dis. 2021 Dec;13(12):6838-6847. doi: 10.21037/jtd-21-931.
7
Thymic tumours and their special features.胸腺肿瘤及其特征。
Eur Respir Rev. 2021 Oct 20;30(162). doi: 10.1183/16000617.0394-2020. Print 2021 Dec 31.